RCKT at a glance
ROCKET PHARMACEUTICALS, INC. (RCKT, SEC CIK 1281895) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on October 6, 2026 and Form 4 insider filings as recently as September 15, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ROCKET PHARMACEUTICALS, INC. (RCKT) reported revenue of $0 and a net loss of $223.1 million. Diluted EPS was -$2.01.
- As of June 30, 2026, 30 institutional investment managers tracked by SignalX reported holding ROCKET PHARMACEUTICALS, INC. (RCKT) shares worth $157.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Wilson Martin on September 11, 2026 of 75,364 shares at $3.40 per share.
- In the last 90 days, RCKT insiders reported 0 open-market purchases ($0) and 7 open-market sales ($432K) on Form 4, a net sale of $432K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 7 sells
- Net −$432K
- 13F holders
- 30 funds
- $157.7M · +1 vs prior quarter
- Latest 8-K
- Sep 15, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- No profitability or margin percentages disclosed
- Best-performing program: RP-A501, with $180M PRV monetization and Phase 2 dosing resumed
- Cash deployment: $180M non-dilutive proceeds from completed PRV sale
- Near-term outlook: Danon regulatory-pathway update expected in second half of 2026; launch preparations continue for KRESLADI™
Risk Factors
- No risk factors provided in the submitted excerpt
- Excerpt begins with Item 2 and contains no Item 1A Risk Factors disclosure
- Priority Review Voucher asset purchase agreement dated April 26, 2026 disclosed as a new exhibit
AI summary of the RCKT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Item 7.01 provides only the filing’s standard Regulation FD disclaimer
- No substantive company disclosure or investor-actionable information appears in the provided text
Item EX-99.1: Item EX-99.1
- FDA alignment preserves RP-A501’s pivotal Phase 2 path and potential accelerated approval strategy in Danon disease
- Pivotal population set at 12 male patients receiving 3.8 × 10¹³ GC/kg; first three patients count toward efficacy population
Item 5.02: Departure/Appointment of Directors or Principal Officers
- New severance program covers U.S. employees, increasing retention protection and potential change-in-control transaction costs
- CEO Gaurav Shah receives $674,856 base salary and 60% target bonus
AI summaries of RCKT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RCKT
Don't miss the next RCKT filing
- Alerts as it files. A push when RCKT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RCKT, by share count.
- Ask anything. An AI agent that reads every RCKT filing and answers with sources.
RCKT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Wilson Martin | Sell | Sep 11, 2026 | 75,364 | $3.40 |
| Shah Gaurav | Sell | Aug 18, 2026 | 2,293 | $3.38 |
| Wilson Martin | Sell | Aug 18, 2026 | 631 | $3.38 |
| Shah Gaurav | Sell | Aug 13, 2026 | 2,837 | $3.38 |
| Wilson Martin | Sell | Aug 13, 2026 | 3,493 | $3.38 |
| Chaudhuri Sarbani | Sell | Aug 11, 2026 | 4,701 | $3.50 |
| Stevens Christopher James | Sell | Aug 11, 2026 | 36,658 | $3.50 |
| Stevens Christopher James | A | Aug 3, 2026 | 73,313 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $0 | $0 |
| Operating Income | - | -$273.2M | -$231.7M |
| Net Income | -$245.6M | -$258.7M | -$223.1M |
| Balance Sheet | |||
| Total Assets | $566.3M | $527.7M | $330.4M |
| Equity | - | $463.2M | $277.2M |
| ROE | - | -55.9% | -80.5% |
| Per Share | |||
| EPS | $-2.92 | $-2.73 | $-2.01 |
| Cash Flow | |||
| Operating CF | - | -$209.7M | -$190.0M |
| CapEx | $16.4M | $5.9M | $440K |
Source: XBRL data in ROCKET PHARMACEUTICALS, INC. (RCKT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate RCKT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 30 | $157.7M |
| Q1 2026 | 29 | $158.5M |
| Q4 2025 | 26 | $149.2M |
| Q3 2025 | 27 | $126.9M |
| Q2 2025 | 26 | $78.1M |
| Q1 2025 | 22 | $138.8M |
| Q4 2024 | 18 | $223.4M |
| Q3 2024 | 13 | $188.2M |
- BlackRock+2.09M (+27%)
- JPMorgan Chase & Co+1.19M (+150%)
- Vanguard Portfolio Management LLC+1.12M (+24%)
- Goldman Sachs Group+1.11M (+65%)
- Millennium Management+882.2K (+28%)
- State Street Corp−2.67M (-59%)
- D.E. Shaw & Co−1.22M (-56%)
- Morgan Stanley−957.6K (-47%)
- Two Sigma Investments−781.9K (-71%)
- T. Rowe Price Group−672.5K (-78%)
- Citadel Advisors LLC+71.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 191 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RCKT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 6, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 8-K | Aug 27, 2026 | - | Analysis | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | May 28, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
RCKT SEC filings: frequently asked questions
Are RCKT insiders buying or selling?
In the last 90 days, ROCKET PHARMACEUTICALS, INC. (RCKT) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $432,467 by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold RCKT stock?
As of June 30, 2026, the largest ROCKET PHARMACEUTICALS, INC. (RCKT) holders among the 13F filers tracked by SignalX were BlackRock ($33.9 million), Vanguard Portfolio Management LLC ($19.9 million), Citigroup ($16.6 million), Millennium Management ($13.7 million), Vanguard Capital Management LLC ($12.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RCKT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ROCKET PHARMACEUTICALS, INC. (RCKT) reported revenue of $0 and a net loss of $223.1 million. Diluted EPS was -$2.01. The figures come from the XBRL data in the 10-K.
What did RCKT report in its latest 8-K?
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an 8-K on September 15, 2026 reporting Item 7.01 (Regulation FD Disclosure). Item 7.01 provides only the filing’s standard Regulation FD disclaimer.
What are the latest RCKT SEC filings?
ROCKET PHARMACEUTICALS, INC. (RCKT) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on October 6, 2026 and a Form 4 insider filing on September 15, 2026.
What is RCKT's SEC CIK number?
ROCKET PHARMACEUTICALS, INC. (RCKT)'s SEC Central Index Key (CIK) is 1281895. EDGAR lists every RCKT filing under that number.
Ask anything about RCKT
The research agent reads RCKT's filings, financials, insider trades and 13F holders, then answers with sources.